Indeed, CD163+ is required for their protumoral activities (Shiraishi et al, 2018) and is a prognostic marker for specific sarcoma subtypes such as embryonal rhabdomyosarcoma (ERMS; Kather et al, 2019), whereas in OSs, CD163+ M2 macrophages are proangiogenic, facilitating cancer cell extravasation and promoting the metastatic process (Dumars et al, 2016; Han et al, 2016; Gomez‐Brouchet et al, 2017). The gene discussed is CD163; the disease is embryonal rhabdomyosarcoma.